DNLI Stock Analysis: Buy, Sell, or Hold?
DNLI - Denali Therapeutics Inc. Common Stock
$25.83
-0.15 (-0.58%)
▼
5d:
+4.45%
30d:
+33.49%
90d:
+31.25%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.6/10
Get Alerted When DNLI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DNLI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DNLI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DNLI is currently trading at $25.83, which is considered extended relative to its 30-day fair value range of $19.98 to $24.66.
Technical Outlook: Technically, DNLI is in a uptrend. Immediate support is located at $23.21, while resistance sits at $26.80.
Market Sentiment: DNLI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.93 (+31.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DNLI is in a uptrend. Immediate support is located at $23.21, while resistance sits at $26.80.
Market Sentiment: DNLI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.93 (+31.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$19.98 -
$24.66
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.4% below Wall St target ($33.93)
Trading Range Analysis
30-Day Trading Range
$19.98 -
$24.66
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$23.21
Resistance Level
$26.80
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.42
Wall Street Target
$33.93
(+31.4%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 02, 2026 10:42 PM ET
Data refreshes hourly during market hours. Next update: 11:42 PM
Data refreshes hourly during market hours. Next update: 11:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNLI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Alexander O Schuth
SELL
17218 shares
2026-01-06
Ryan J Watts
SELL
35198 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
